| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7cb4a3168b16e5097cea4fbe16d0c10f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06dc5935320f87c58a1f530f13437b7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6456bb8a4351d12fb6e6b4395b69583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_322e95ba9b7fd6970b19b09f93fbc132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27e1ea5f65e8f958e48f1a9d53fdbb45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-689 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2003-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc6e3f03f9fd3061f810c051bd631f4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1321912956ac44fd655b0ac2d0cbbc25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eb76fc484598daeead9d77697a84b2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd0dd2e590fc67187acf1a1891b995d0 |
| publicationDate |
2005-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1581650-A2 |
| titleOfInvention |
Molecular signature and assay for fluoroquinoline resistance in bacillus anthracis |
| abstract |
The preferred therapeutic for human anthrax infections are therapeutics from the fluoroquinolone class, in particular, Ciprofloxacin (CIP). This invention discloses the molecular basis for fluoroquinolone (CEP in particular) action and provides the molecular signatures which form the basis of diagnostic assays. This invention further discloses nucleotide signatures associated with CIP-resistance are useful in diagnostic tests to rapidly identify CIP resistant B. anthracis and to infer the level of resistance of these mutant strains. According to this invention, the diagnostic potential of the molecular signatures is illustrated using a primer extension assay. Further, PCR and extension primers which allow the detection of these signatures are disclosed. |
| priorityDate |
2002-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |